Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 6/20 | 0.60 |
| ▸ | HTR1D | P28221 | 4/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | HTR1F | P30939 | 1/20 | 0.51 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9336211 | 0.97 | HTR1B (0.63) | HTR1BHTR1DHTR6HTR1FNR2E1 | |
| Phenylacetic Acid SCHEMBL8116464 | 0.88 | HTR1B (0.52) | HTR1BHTR1DHTR6HTR1FNR2E1 | |
| Oxalic Acid SCHEMBL7540979 | 0.85 | HTR1B (0.57) | HTR1BHTR1DHTR6HTR1FNR2E1 | |
| Oxalic Acid SCHEMBL27452775 | 0.84 | HTR1B (0.60) | HTR1BHTR1DHTR6HTR1FNR2E1 | |
| SCHEMBL11841764 | 0.84 | HTR1F (0.53) | HTR1BHTR1DHTR1FKMT2AHTR1A | |
| Oxalic Acid SCHEMBL7540449 | 0.82 | HTR1B (0.66) | HTR1BHTR1DHTR6NR2E1KMT2A | |
| SCHEMBL11334169 | 0.81 | HTR1F (0.74) | HTR1BHTR1DHTR1FKMT2AHTR1A | |
| SCHEMBL7657810 | 0.81 | HTR1F (0.73) | HTR1BHTR1DHTR6HTR1FNR2E1 | |
| Oxalic Acid SCHEMBL7543349 | 0.80 | HTR1B (0.66) | HTR1BHTR1DHTR6NR2E1KMT2A | |
| Oxalic Acid SCHEMBL8654818 | 0.80 | KMT2A (0.72) | HTR1BHTR1DHTR6NR2E1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032192-A1 | Treatment of vasodilatory headache | VERNALIS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| EP-1104292-A2 | TREATMENT OF VASODILATORY HEADACHE | Vernalis Limited (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009099-A2 | TREATMENT OF VASODILATORY HEADACHE | VERNALIS LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
| US-5827871-A | VASODILATION DISORDERS, ESPECIALLY MIGRAINE HEADACHES; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM PLC (GB) | 1998-10-27 | — | — | US | disclosed |
| EP-0603432-B1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1998-10-21 | — | — | EP | disclosed |
| EP-0591280-B1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5637611-A | Medicaments | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-06-10 | — | — | US | disclosed |
| US-5464864-A | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-11-07 | — | — | US | disclosed |
| EP-0603432-A1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1994-06-29 | — | — | EP | disclosed |
| EP-0591280-A1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000086-A1 | USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032192-A1 | Treatment of vasodilatory headache | CNR1, CNR2, EDNRA | OPRM1 137/4885HTR1B 71/4885HTR1D 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.